Abbreviations ADVANCE: action in diabetes and vascular disease AMI: acute myocardial infarction BID: twice daily bpm: beats per minute CI: confidence interval CVOT: cardiovascular outcome trial ELIXA: Evaluation of LIXisenatide in Acute coronary syndrome FIGHT: Functional Impact of GLP-1 for Heart Failure Treatment GLP-1 RA: glucagon-like peptide-1 receptor agonist HF: heart failure HR: heart rate LAR: long-acting release LEADER: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results LIVE: Effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes LS: least squares PK: pharmacokinetic QD: once daily QW: once weekly SE: standard error T2DM: type 2 diabetes mellitus References Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR

A: Insurers still use BMI because it gives them a quick, standard way to decide who may qualify for treatments like weight-loss surgery
Read current terms before submitting payment
Clear and Targeted Labeling : GLP-1 Friendly or nutrient-focused badges help consumers quickly identify products that meet their dietary needs, while also reinforcing the brands commitment to health-focused innovation
Coresight Research found that 40% of GLP-1 users specifically say that fit guidance or body measurement tools would be most helpful during their weight-loss transition [Coresight, 2025]